Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Renovo Splits Juvidex Into Two
According to the company sources, the new product, an injection formulation of the Juvidex active ingredient M6P will be used in the treatment for tendon adhesions, and the
According to the company sources, the new product, an injection formulation of the Juvidex active ingredient M6P will be used in the treatment for tendon adhesions, and the
This crucial phase III clinical trial is designed to evaluate the effectiveness and safety of lubiprostone in Japanese patients with CIC over a 28-day treatment period. This trial
The collaboration draws synergy from Lilly’s insulin expertise and Medtronic’s diabetes technologies. The alliance is expected to enhance awareness level of the people and help them benefit from
Vernakalant is an investigational candidate used for the treatment of atrial fibrillation. As per the terms of the agreement, effectiveness of the agreement triggers an initial payment of
CLL is caused when too many abnormal white blood cells are developed in blood and bone marrow. The abnormal cells surpass the number of normal white blood cells,
Drug compositions were dynamic and customers switched to new drugs with extra features in a very short period. But, officials demanded a fresh licence to change formulation which
Luciano Rossetti of Merck Research Laboratories, said: “Merck is pleased that we are now able to supply Tredaptive in approved markets and continue our long-standing commitment to help
Now the government intends to raise the volume figure to 30% over the next three years. This has motivated many major overseas generics players to start operations in
The company further plans to start a development program to examine the investigational product as an oral treatment for male hypogonadism, also known as low testosterone (low T).
For the third quarter of fiscal 2009, the company reported product revenue of $9,174,000 for the third quarter of fiscal 2009, a 12.7% increase, compared with $8,139,000 in